Related Experiment Video

Updated: Aug 11, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials

Maria Thomas1, Johann Greil, Olaf Heidenreich

  • 1Department of Molecular Biology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tuebingen, Auf der Morgenstelle 15, 72076 Tuebingen, Germany.

Acta Pharmacologica Sinica
|February 24, 2006
PubMed

Insights

RNA interference (RNAi) is a powerful tool for studying gene function and offers potential therapeutic strategies for diseases. This review focuses on targeting leukemia-specific genes using RNAi for cancer treatment.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • RNA interference (RNAi) is a crucial research method for gene function analysis across diverse organisms.
  • RNAi's high efficacy and specificity suggest potential therapeutic applications for human diseases.

Purpose of the Study:

  • To review recent advancements in targeting leukemia-specific genes using RNA interference.
  • To discuss challenges and strategies for the clinical application of RNAi in leukemia treatment.

Main Methods:

  • Literature review of RNA interference applications in leukemia research.
  • Analysis of oncogene targeting strategies for gene silencing.

Main Results:

  • Leukemia-specific genes, particularly fusion proteins from chromosomal translocations, are promising RNAi targets.
  • These targets are often essential for malignant phenotype maintenance and exclusively expressed in cancer cells.

Conclusions:

  • RNA interference holds significant promise as a therapeutic strategy for leukemia.
  • Overcoming challenges in clinical application is key to realizing RNAi's full therapeutic potential in oncology.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...